Welcome to our dedicated page for ACCUSTEM SCIENCES news (Ticker: ACUT), a resource for investors and traders seeking the latest updates and insights on ACCUSTEM SCIENCES stock.
AccuStem Sciences Inc. develops clinical-stage cancer diagnostics centered on proprietary molecular testing for screening, treatment planning, and monitoring. Its news commonly covers the MSC test, a non-invasive blood-based MicroRNA Signature Classifier that analyzes 24 circulating microRNAs to classify lung nodules by malignancy risk in lung cancer screening workflows.
Company updates also include StemPrintER studies in breast cancer, collaborations with diagnostic and clinical research organizations, blood-sample access agreements, testing infrastructure for microRNA extraction, investor presentations, and board-level share purchase announcements. These developments reflect AccuStem’s focus on cancer biology, including tumor stemness, and on translating molecular assays into clinical diagnostic use.
AccuStem Sciences, Inc. (OTCQB: ACUT) announced the appointment of Sean McDonald to its Board of Directors, increasing the board to five members. McDonald brings extensive experience in building healthcare organizations and securing funding for early-stage companies. Currently the CEO of Ocugenix, he previously held leadership roles at Precision Therapeutics and Automated Healthcare. His background will support AccuStem's mission to innovate cancer diagnostics through genomic testing. CEO Wendy Blosser expressed confidence in McDonald's ability to advance the company's growth strategy.
AccuStem Sciences (OTCQB: ACUT) announced the adjournment of its 2022 annual stockholders' meeting due to a lack of quorum. Originally scheduled for October 10, 2022, the meeting has been rescheduled for October 14, 2022. Proxies from stockholders represent approximately 36% of the outstanding shares. The company aims to solicit additional votes during this period. Stockholders of record as of September 14, 2022, are encouraged to vote by October 13, 2022. AccuStem focuses on enhancing cancer patient outcomes through proprietary molecular testing.
AccuStem Sciences, Inc. (OTCQB: ACUT) has received a new patent (No. 11,441,191) for its innovative StemPrintER test, which stratifies early-stage breast cancer patients based on their recurrence risk. The patented method assesses the stemness of tumors, indicating cancer progression potential and responsiveness to treatment. High stemness patients may face up to four times the risk of distant recurrence compared to those with low stemness. CEO Wendy Blosser emphasized that this patent strengthens their intellectual property portfolio and supports their commitment to healthcare innovation.
AccuStem Sciences, Inc. (OTCQB: ACUT) announced that Chairman Gabriele Cerrone has purchased 20,000 shares of ACUT, increasing his total holdings to 3,821,226 shares. This purchase reflects Cerrone's confidence in the company's trajectory and potential in the life sciences sector focused on cancer treatment. AccuStem is dedicated to improving cancer patient outcomes through innovative solutions and comprehensive care approaches.
AccuStem Sciences, Inc. (OTCQB: ACUT) announced that its Chairman, Gabriele Cerrone, purchased an additional 9,447 shares, raising his total holdings to 3,801,226 shares. Cerrone expressed confidence in the company's direction, aligning his interests with fellow shareholders. AccuStem is focused on enhancing cancer patient outcomes, aiming to provide essential tools and answers in oncology while fostering healthcare innovation.
AccuStem Sciences has announced its uplisting from the OTC Pink Sheets to the OTCQB, effective April 14, 2022, under the ticker "ACUT." This change aims to enhance visibility for retail and institutional investors and improve trading liquidity. The OTCQB is recognized by the SEC and requires companies to meet ongoing listing standards. CEO Wendy Blosser noted that this uplisting is crucial for expanding the shareholder base and raising capital for innovative cancer treatment products.
AccuStem Sciences announced a Common Stock Purchase Agreement with Tiziana Life Sciences, resulting in Tiziana purchasing 1,337,970 shares at $2.00 each, generating gross proceeds of $2,675,940. This transaction follows the Supplemental Demerger Agreement from October 5, 2021. The shares were not registered under the Securities Act of 1933, thus limiting their sale in the U.S. The company remains focused on enhancing cancer patient outcomes and highlights the inherent risks in forward-looking statements regarding its business strategies and financial health.
AccuStem Sciences, Inc. (OTC Pink: ACUT) announced that its common shares are now DTC eligible for electronic clearing and settlement in the U.S., enhancing trading efficiency and liquidity. This milestone is aimed at increasing awareness and expanding the shareholder base, moving the company closer to a NASDAQ listing. On March 23, 2022, shareholders of old AccuStem ADSs will convert to U.S. shares at a rate of 1:10. The company emphasizes its dedication to improving cancer patient outcomes while highlighting potential risks in its forward-looking statements.
AccuStem Sciences plans to uplist to the Nasdaq Capital Market following the formation of a new executive leadership team, including Wendy Blosser as CEO. With extensive experience in oncology, Blosser aims to enhance product commercialization. Alongside her, Jeff Fensterer and Joe Flanagan join as COO and CBO respectively to leverage their backgrounds in strategic growth. The company is also moving its headquarters to Phoenix, Arizona. This leadership assembly is seen as a pivotal step in developing AccuStem's clinical research and business strategies.